Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study

ConclusionsThis retrospective study showed that TARE therapy resulted in minimal toxicity in patients with HBV-derived HCC. Patients with CP A or BCLC A disease had superior survival outcomes compared to patients with CP B and BCLC B/C disease. These findings suggest that TARE is a viable treatment option for certain patient groups with HCC tumors secondary to HBV infection.
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research

Related Links:

Bioinformatics analysis of LINC01554 and its co‑expressed genes in hepatocellular carcinoma. Oncol Rep. 2020 Nov;44(5):2185-2197 Authors: Li L, Huang K, Lu Z, Zhao H, Li H, Ye Q, Peng G Abstract Hepatocellular carcinoma (HCC) is a leading cause of cancer‑related morbidity and mortality globally. Despite the remarkable improvements in comprehensive HCC treatment, the underlying mechanistic details of HCC remain elusive. We screened HCC patients for differentially expressed genes (DEGs) using the Gene Expression Omnibus (GSE113850) and The Cancer Genome Atlas (TCGA) datasets. LINC01554 expressio...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
CONCLUSION: Our findings confirm previous evidence from the phase III REFLECT study. The majority of patients in this Chinese sample were suffering from concomitant hepatitis B virus-related HCC. However, further analysis suggested that baseline characteristics, changes in serum biomarkers and gene sequencing may hold the key for predicting lenvatinib responses. Further large-scale prospective studies that incorporate more basic medical science measures should be conducted. PMID: 32874058 [PubMed - in process]
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Tags: World J Gastroenterol Source Type: research
This study aimed to explore the prognostic factors that affect the PFS in HCC and establish an individualized prediction model.MethodsWe included 2890 patients with hepatitis B-related HCC hospitalized at Beijing Ditan Hospital, Capital Medical University and randomly divided into training and validation cohort. Cox multivariate regression was used to analyze independent risk factors affecting the 1-year PFS of HCC, and an artificial neural networks (ANNs) model was constructed. C-index, calibration curve, and decision curve analysis were used to evaluate the performance of the model.ResultsThe median survival time was 26....
Source: Hepatology International - Category: Infectious Diseases Source Type: research
Conclusions: The results obtained from these 5 cases demonstrate impressive tumor control from the combination of SBRT and checkpoint inhibitors in patients with large tumors of advanced HCC. Further prospective trials are warranted.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: While there is a certain overlap between the results of the current study and published transcriptomic profiles of non-transplanted livers with steatosis, we have identified discrete characteristics of the non-alcoholic fatty liver disease in liver grafts potentially utilizable for the establishment of predictive signature. Introduction Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in industrialized countries, its prevalence being estimated at 19–31.3% (1). It encompasses a range of conditions that are thought to arise from fatty liver (simple steatosis) throu...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Conclusion: When the therapeutic approach is used in elderly patients with HCC, the patient's performance status, liver function, and stage of cancer should be considered, and its use should not be restricted to those of advanced age.
Source: In Vivo - Category: Research Authors: Tags: Clinical Studies Source Type: research
Rationale: Synchronous gastric carcinoma and hepatocellular carcinoma (HCC) is rare. It is hard to distinguish synchronous HCC from metastatic liver cancer in this condition. The treatment and prognosis is quite different for synchronous HCC of gastric carcinoma and liver metastasis of gastric carcinoma. Patient concerns: A 68-year-old man with a chief complaint of epigastric pain for 1 year, accompanied by reflux and belching. The patient was diagnosed with gastric carcinoma (cT4NxM0) and laparoscopy-assisted radical distal gastrectomy was performed. This was followed by chemotherapy of FOLFOX regimen. However, a liv...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
ConclusionsIL-37b inhibits HCC growth, metastasis and epithelial mesenchymal transition by regulating IL-6/STAT3 signaling. Serum IL-37b may be a biomarker for HBV-HCC and its staging.
Source: Hepatobiliary and Pancreatic Diseases International - Category: Gastroenterology Source Type: research
A 68-year-old woman with hepatitis B virus infection was referred for numbness of her legs. Transarterial chemoembolization was performed for hepatocellular carcinoma (HCC) with portal tumor thrombus 3 months previously. Magnetic resonance imaging showed a metastatic tumor of thoracic vertebrae. Radiation shrank the metastatic lesion, but the leg paralysis was irreversible. After 1 month, her hemoglobin level decreased, and an endoscopy showed a small polyp at the anterior wall of the gastric angle (Figure A), which was not observed during the previous examination 3 months earlier.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Electronic Image of the Month Source Type: research
Question: A 54-year-old man was referred to our hospital with a 1-month history of intermittent tarry to bloody stool. His medical history included hepatitis B –related liver cirrhosis and hepatocellular carcinoma (HCC). His hepatoma was diagnosed 1 year earlier (American Joint Committee on Cancer Staging T3aN0M0) , and he was treated with radiofrequency ablation and tumor embolization. The tumor recently progressed with portal vein tumor thrombosis (Fig ure A). He underwent sorafenib therapy; however, the drug was discontinued after the bleeding episode.
Source: Gastroenterology - Category: Gastroenterology Authors: Tags: Clinical Challenges and Images in GI Source Type: research
More News: Bilirubin | Cancer | Cancer & Oncology | Carcinoma | Children | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver | Liver Cancer | Radiology | Study | Thrombosis | Toxicology | Urology & Nephrology